



## ASX / MEDIA RELEASE Melbourne, Australia Tuesday, 16 March, 2010

### COMPUMEDICS LIMITED AUDIO STREAM

COMPUMEDICS LIMITED (CMP) provides the opportunity to listen to an audio broadcast with Mr. David Burton, Chairman, Mr. David Lawson, Chief Financial Officer and Boardroomradio in a presentation titled "Corporate and capitalisation Strategy 2010".

To listen, simply go to:

brr.com.au/event/64746

The presentation details are as follows:

# Questions and answers on the current strategy of the Company, including the capitalisation strategy

- Presented by Mr. David Burton, Executive Chairman and Mr. David Lawson, Chief Financial Officer Compumedics Group
- Tuesday 16 March 2010 at 1:00pm AEST

To listen, simply click on the Windows Media Player, QuickTime or MP3 icon.

Additionally, the presentation can be accessed at boardroomradio.com where it will also be archived for future on-demand listening – if you miss the live presentation, you can log on later to hear the news.

Yours faithfully

David Lawson Company Secretary

#### For further information, please contact:

David Burton Executive Chairman & CEO Compumedics Tel: +61 3 8420 7300 David Lawson Chief Financial Officer Compumedics Tel: +61 8420 7300

#### **Investor Relations & Media Enquires:**

Mr Rod North Executive Director Bourse Communications Pty Ltd Phone: +61 3 9510 8309 Mobile: +61 (0) 408 670 706

#### **About Compumedics**

Compumedics Limited, founded in 1987, is a global leader in the design and manufacture of diagnostic technologies for sleep disorders, neurophysiology and cardiology. In 1987 Compumedics established Asia Pacific's first fully computerised sleep laboratory. Compumedics holds 80% share of the Australian sleep-diagnostic market, and has a major and rapidly growing presence in the US, European and Asian marketplaces for its sleep, neurological and Doppler blood-flow diagnostic monitoring devices. In 1995 the company was selected to supply equipment to the US Sleep Heart Health Study, the world's largest sleep study of its kind, currently exceeding 14,000 studies with 20,000 patients scheduled by 2008. With headquarters in Melbourne, Australia and offices in the United States, and Europe the products are distributed in over 50 countries. In 1998 Compumedics was awarded the overall Australian Exporter of the Year. In 2000 Compumedics was listed on the Australian Stock Exchange. In 2002, Compumedics acquired US-based Neuroscan - the world's leading supplier of instruments for brain-research. In the US - the world's largest medical device market - Neuroscan holds around 90% of the market for brain-research products. In 2003 Compumedics was awarded the Frost & Sullivan Award for Market Expansion Strategy. In 2004, Compumedics acquired German-based DWL Elektronishe GmbH, enabling Compumedics to expand its global operations into the neurovascular and cardio-vascular diagnostic fields. In 2006, Compumedics was awarded the Frost and Sullivan Technology Leadership award for the innovative Somté recorder product. **In 2007**, Compumedics and Chairman were inducted into the Victorian Manufacturing Hall of Fame. In 2008 the DWL division received the top 100 German Innovation award. With 20,000 systems installed globally across the finest hospital, universities and clinics the Compumedics sales have grown more than 4 fold from \$9 million (1999) to \$38 million (2009). In 2009 Compumedics was awarded a design award for its Grael® PSG/EEG premium laboratory based product. www.compumedics.com